How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study

Armando Tripodi, Lidia Padovan, Sophie Testa, Cristina Legnani, Veena Chantarangkul, Erica Scalambrino, Silvia Ludovici, Laura Bassi, Flora Peyvandi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). The degree of interference of apixaban with coagulation parameters has not been thoroughly investigated. Methods: Increasing amounts of apixaban were added to aliquots of a pooled normal plasma (PNP) to mimic a large range of concentrations (n=8) that are observed in treated patients. Upon preparation, samples were stored frozen and tested for a vast array of coagulation parameters (including procoagulant and anticoagulant factors) in three laboratories, using three widely used coagulation platforms (reagent/coagulometer combinations). Results: Results for each parameter were expressed as ratios of the value corresponding to each apixaban concentration to the value corresponding to the PNP without apixaban. By definition, ratios higher or lower than the unity define overestimation or underestimation, respectively. Prothrombin and activated partial thromboplastin times were barely prolonged by apixaban 200 ng/mL (ratios

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Hemostatics
Anticoagulants
Multicenter Studies
Coagulation
Plasmas
Factor Xa
Partial Thromboplastin Time
Thromboplastin
Prothrombin
apixaban

Keywords

  • antithrombin
  • antithrombotic drugs
  • coagulation factor assays
  • protein C
  • protein S
  • thrombosis

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. / Tripodi, Armando; Padovan, Lidia; Testa, Sophie; Legnani, Cristina; Chantarangkul, Veena; Scalambrino, Erica; Ludovici, Silvia; Bassi, Laura; Peyvandi, Flora.

In: Clinical Chemistry and Laboratory Medicine, Vol. 53, No. 2, 01.02.2015, p. 265-273.

Research output: Contribution to journalArticle

Tripodi, Armando ; Padovan, Lidia ; Testa, Sophie ; Legnani, Cristina ; Chantarangkul, Veena ; Scalambrino, Erica ; Ludovici, Silvia ; Bassi, Laura ; Peyvandi, Flora. / How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. In: Clinical Chemistry and Laboratory Medicine. 2015 ; Vol. 53, No. 2. pp. 265-273.
@article{26b43d9f56d742719561fe825a5bb9a2,
title = "How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study",
abstract = "Background: Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). The degree of interference of apixaban with coagulation parameters has not been thoroughly investigated. Methods: Increasing amounts of apixaban were added to aliquots of a pooled normal plasma (PNP) to mimic a large range of concentrations (n=8) that are observed in treated patients. Upon preparation, samples were stored frozen and tested for a vast array of coagulation parameters (including procoagulant and anticoagulant factors) in three laboratories, using three widely used coagulation platforms (reagent/coagulometer combinations). Results: Results for each parameter were expressed as ratios of the value corresponding to each apixaban concentration to the value corresponding to the PNP without apixaban. By definition, ratios higher or lower than the unity define overestimation or underestimation, respectively. Prothrombin and activated partial thromboplastin times were barely prolonged by apixaban 200 ng/mL (ratios",
keywords = "antithrombin, antithrombotic drugs, coagulation factor assays, protein C, protein S, thrombosis",
author = "Armando Tripodi and Lidia Padovan and Sophie Testa and Cristina Legnani and Veena Chantarangkul and Erica Scalambrino and Silvia Ludovici and Laura Bassi and Flora Peyvandi",
year = "2015",
month = "2",
day = "1",
doi = "10.1515/cclm-2014-0531",
language = "English",
volume = "53",
pages = "265--273",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "2",

}

TY - JOUR

T1 - How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study

AU - Tripodi, Armando

AU - Padovan, Lidia

AU - Testa, Sophie

AU - Legnani, Cristina

AU - Chantarangkul, Veena

AU - Scalambrino, Erica

AU - Ludovici, Silvia

AU - Bassi, Laura

AU - Peyvandi, Flora

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background: Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). The degree of interference of apixaban with coagulation parameters has not been thoroughly investigated. Methods: Increasing amounts of apixaban were added to aliquots of a pooled normal plasma (PNP) to mimic a large range of concentrations (n=8) that are observed in treated patients. Upon preparation, samples were stored frozen and tested for a vast array of coagulation parameters (including procoagulant and anticoagulant factors) in three laboratories, using three widely used coagulation platforms (reagent/coagulometer combinations). Results: Results for each parameter were expressed as ratios of the value corresponding to each apixaban concentration to the value corresponding to the PNP without apixaban. By definition, ratios higher or lower than the unity define overestimation or underestimation, respectively. Prothrombin and activated partial thromboplastin times were barely prolonged by apixaban 200 ng/mL (ratios

AB - Background: Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). The degree of interference of apixaban with coagulation parameters has not been thoroughly investigated. Methods: Increasing amounts of apixaban were added to aliquots of a pooled normal plasma (PNP) to mimic a large range of concentrations (n=8) that are observed in treated patients. Upon preparation, samples were stored frozen and tested for a vast array of coagulation parameters (including procoagulant and anticoagulant factors) in three laboratories, using three widely used coagulation platforms (reagent/coagulometer combinations). Results: Results for each parameter were expressed as ratios of the value corresponding to each apixaban concentration to the value corresponding to the PNP without apixaban. By definition, ratios higher or lower than the unity define overestimation or underestimation, respectively. Prothrombin and activated partial thromboplastin times were barely prolonged by apixaban 200 ng/mL (ratios

KW - antithrombin

KW - antithrombotic drugs

KW - coagulation factor assays

KW - protein C

KW - protein S

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84920886981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920886981&partnerID=8YFLogxK

U2 - 10.1515/cclm-2014-0531

DO - 10.1515/cclm-2014-0531

M3 - Article

C2 - 25153405

AN - SCOPUS:84920886981

VL - 53

SP - 265

EP - 273

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 2

ER -